| Literature DB >> 19949570 |
Brien J Smith1, Erik K St Louis, John M Stern, Chad Green, Thomas Bramley.
Abstract
When discussing AED conversion in the clinic, both the patient and physician perspectives on the goals and risks of this change are important to consider. To identify patient-reported and clinician-perceived concerns, a panel of epilepsy specialists was questioned about the topics discussed with patients and the clinician's perspective of patient concerns. Findings of a literature review of articles that report patient-expressed concerns regarding their epilepsy and treatment were also reviewed. Results showed that the specialist panel appropriately identified patient-reported concerns of driving ability, medication cost, seizure control, and medication side effects. Additionally, patient-reported concerns of independence, employment issues, social stigma, medication dependence, and undesirable cognitive effects are important to address when considering and initiating AED conversion.Entities:
Keywords: Epilepsy; antiepileptic drugs; conversion; patient preferences.
Year: 2009 PMID: 19949570 PMCID: PMC2730003 DOI: 10.2174/157015909788848947
Source DB: PubMed Journal: Curr Neuropharmacol ISSN: 1570-159X Impact factor: 7.363
Topics Reported by the SPECTRA Panel as Discussed with Patients
| Topics | n |
|---|---|
| Goals of therapy (best QoL, no seizures, no side effects) | 12 (100) |
| Likelihood of having a seizure during conversion | 11 (92) |
| Education regarding difference between short- and long-term side effects | 11 (92) |
| Importance of compliance during therapy conversion | 9 (75) |
| Need to suspend driving | 9 (75) |
n = number of individual panel members from the total panel size of 12 specialists who discussed the topic with patients.
Patient Concerns as Reported by the SPECTRA Panel
| Patient Concerns About Conversion | n |
|---|---|
| Cost of medication | 11 (92) |
| Loss/suspension of driving privilege | 10 (83) |
| Potential loss of seizure control | 10 (83) |
| New or worsening side effects | 10 (83) |
| Drug interactions | 8 (67) |
| Frequency of dosing | 7 (58) |
n = number of individual panel members from the total panel size of 12 specialists who reported patient concerns